{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:37:48Z","timestamp":1793504268542,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Drugs for Neglected Diseases initiative","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"CNPq- National Council for Scientific and Technological Development","award":["302622\/2017-9, 306971\/2018-6"],"award-info":[{"award-number":["302622\/2017-9, 306971\/2018-6"]}]},{"name":"Carlos Chagas Filho Research Foundation of Rio de Janeiro State","award":["E26\/202.569\/20"],"award-info":[{"award-number":["E26\/202.569\/20"]}]},{"name":"PAEF-IOC-FIOCRUZ, Oswaldo Cruz Foundation","award":["Support for Biological Collections"],"award-info":[{"award-number":["Support for Biological Collections"]}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo - FAPESP","award":["2015\/09080-2 and 2016\/23405-4"],"award-info":[{"award-number":["2015\/09080-2 and 2016\/23405-4"]}]},{"name":"Capes - Brazilian Federal Agency for Support and Evaluation of Graduate Education","award":["Code 001"],"award-info":[{"award-number":["Code 001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Treatment of visceral leishmaniasis in Brazil still relies on meglumine antimoniate, with less than ideal efficacy and safety, making new therapeutic tools an urgent need. The oral drug miltefosine was assayed in a phase II clinical trial in Brazil with cure rates lower than previously demonstrated in India. The present study investigated the susceptibility to miltefosine in 73 Brazilian strains of Leishmania infantum from different geographic regions, using intracellular amastigote and promastigote assays. The EC50 for miltefosine of 13 of these strains evaluated in intracellular amastigotes varied between 1.41 and 4.57 \u03bcM. The EC50 of the 73 strains determined in promastigotes varied between 5.89 and 23.7 \u03bcM. No correlation between in vitro miltefosine susceptibility and the presence of the miltefosine sensitive locus was detected among the tested strains. The relatively low heterogeneity in miltefosine susceptibility observed for the 73 strains tested in this study suggests the absence of decreased susceptibility to miltefosine in Brazilian L. infantum and does not exclude future clinical evaluation of miltefosine for VL treatment in Brazil.<\/jats:p>","DOI":"10.3390\/microorganisms9061228","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"1228","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["In Vitro Susceptibility to Miltefosine of Leishmania infantum (syn. L.\u00a0chagasi) Isolates from Different Geographical Areas in Brazil"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-8091","authenticated-orcid":false,"given":"Caroline Ricce","family":"Espada","sequence":"first","affiliation":[{"name":"Departamento de Parasitologia, Instituto de Ci\u00eancias Biom\u00e9dicas, Universidade de S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-2987","authenticated-orcid":false,"given":"Erica V. de Castro","family":"Levatti","sequence":"additional","affiliation":[{"name":"Departamento de Parasitologia, Instituto de Ci\u00eancias Biom\u00e9dicas, Universidade de S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-6280","authenticated-orcid":false,"given":"Mariana C\u00f4rtes","family":"Boit\u00e9","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Pesquisa em Leishmanioses, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Lamounier","sequence":"additional","affiliation":[{"name":"Universidade Federal do Piau\u00ed, Hospital de Doen\u00e7as Tropicais Natan Portela, Teresina, Piau\u00ed 64002-510, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alvar","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cupolillo","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Pesquisa em Leishmanioses, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-2006","authenticated-orcid":false,"given":"Carlos Henrique Nery","family":"Costa","sequence":"additional","affiliation":[{"name":"Universidade Federal do Piau\u00ed, Hospital de Doen\u00e7as Tropicais Natan Portela, Teresina, Piau\u00ed 64002-510, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Rode","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Rio de Janeiro 20010-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-3704","authenticated-orcid":false,"given":"Silvia R. B.","family":"Uliana","sequence":"additional","affiliation":[{"name":"Departamento de Parasitologia, Instituto de Ci\u00eancias Biom\u00e9dicas, Universidade de S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"ref_1","unstructured":"WHO (2021, February 22). Leishmaniasis. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"ref_2","unstructured":"Pan American Health Organization (2020). Leishmaniasis: Epidemiological Report in the Americas, PAHO. Available online: https:\/\/iris.paho.org\/handle\/10665.2\/51742."},{"key":"ref_3","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade (2021, March 25). Letalidade de Leishmaniose Visceral: Brasil, Grandes Regi\u00f5es e Unidades Federadas 2000 a 2019, Available online: https:\/\/antigo.saude.gov.br\/images\/pdf\/2020\/August\/25\/LV-Letalidade.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lindoso, J.A., Cota, G.F., da Cruz, A.M., Goto, H., Maia-Elkhoury, A.N., Romero, G.A., de Sousa-Gomes, M.L., Santos-Oliveira, J.R., and Rabello, A. (2014). Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003136"},{"key":"ref_5","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade (2021, March 22). Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. Leishmaniose Visceral: Recomenda\u00e7\u00f5es Cl\u00ednicas Para Redu\u00e7\u00e3o da Letalidade, Available online: http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/leishmaniose_visceral_reducao_letalidade.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Romero, G.A.S., Costa, D.L., Costa, C.H.N., de Almeida, R.P., de Melo, E.V., de Carvalho, S.F.G., Rabello, A., de Carvalho, A.L., Sousa, A.Q., and Leite, R.D. (2017). Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005706"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"Balasegaram","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"Davidson","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1086\/367843","article-title":"Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis","volume":"36","author":"Syriopoulou","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4269\/ajtmh.18-0949","article-title":"Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil","volume":"101","author":"Carnielli","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ebiom.2018.09.029","article-title":"A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis","volume":"36","author":"Carnielli","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1093\/jac\/dkx283","article-title":"Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: A population pharmacokinetic\/pharmacodynamic study","volume":"72","author":"Dorlo","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis","volume":"56","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","first-page":"1530","article-title":"Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial","volume":"68","author":"Mbui","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dorlo, T.P., Rijal, S., Ostyn, B., de Vries, P.J., Singh, R., Bhattarai, N., Uranw, S., Dujardin, J.C., Boelaert, M., and Beijnen, J.H. (2014). Failure of Miltefosine in Visceral Leishmaniasis Is Associated with Low Drug Exposure. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiu039"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Espada, C.R., Ribeiro-Dias, F., Dorta, M.L., de Araujo Pereira, L.I., de Carvalho, E.M., Machado, P.R., Yokoyama-Yasunaka, J.K., Coelho, A.C., and Uliana, S.R. (2017). Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis. Am. J. Trop. Med. Hyg.","DOI":"10.4269\/ajtmh.16-0811"},{"key":"ref_22","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade (2021, March 25). Secretaria de Vigil\u00e2ncia em Sa\u00fade. Leishmaniose Visceral: O Que \u00e9, Causas, Sintomas, Tratamento, Diagn\u00f3stico e Preven\u00e7\u00e3o, Available online: https:\/\/antigo.saude.gov.br\/images\/pdf\/2020\/August\/25\/LV-Gr--ficos-e-Mapas.pdf."},{"key":"ref_23","first-page":"68","article-title":"In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B","volume":"15","author":"Miguel","year":"2010","journal-title":"Trop. Med. Int. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s42003-021-01658-5","article-title":"Colonization and genetic diversification processes of Leishmania infantum in the Americas","volume":"4","author":"Schwabl","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/AAC.01233-08","article-title":"In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: Correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity","volume":"53","author":"Kumar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv. Parasitol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Alves, F., Bilbe, G., Blesson, S., Goyal, V., Monnerat, S., Mowbray, C., Muthoni Ouattara, G., P\u00e9coul, B., Rijal, S., and Rode, J. (2018). Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clin. Microbiol. Rev., 31.","DOI":"10.1128\/CMR.00048-18"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1039\/D0MD00073F","article-title":"Leishmania infantum isolates exhibit high infectivity and reduced susceptibility to amphotericin B","volume":"11","author":"Greif","year":"2020","journal-title":"RSC Med. Chem."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/6\/1228\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:20Z","timestamp":1760163080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/6\/1228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["microorganisms9061228"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9061228","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]}}}